{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"39"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"63"}],"units":"Participants"}],"description":"Participants who achieved a platelet count \\>=50 Gi/L at any time during the first 6 weeks of Part 1 were reported.","groups":[{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received placebo 37.5 mg QD, and those with a body weight \\>=27 kg received placebo 50 mg QD. Participants of East Asian ancestry received a starting dose of placebo 25 mg QD. Participants aged between 1 and 5 years received placebo 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of placebo 0.8 mg/kg/day.","id":"OG000","title":"Part 1 (Randomized Period)-Placebo"},{"description":"In Part 1, participants aged between 6 and 17 years with a body weight \\<27 kg received eltrombopag 37.5 mg QD, and those with a body weight \\>=27 kg received eltrombopag 50 mg QD. Participants of East Asian ancestry received a starting dose of eltrombopag 25 mg QD. Participants aged between 1 and 5 years received eltrombopag 1.2 mg/kg QD; participants of East Asian ancestry received a starting dose of eltrombopag 0.8 mg/kg/day.","id":"OG001","title":"Part 1 (Randomized Period)-Eltrombopag"}],"paramType":"NUMBER","populationDescription":"ITT Population","reportingStatus":"POSTED","timeFrame":"From Baseline up to Week 6 of Part 1","title":"Number of Participants Achieving a Platelet Count >=50 Gi/L at Any Time During the First 6 Weeks of Part 1","type":"SECONDARY","unitOfMeasure":"Participants"}